Memorial Sloan Kettering Cancer Center MSK Cardio-Oncology Symposium 2026

Date & Location Thursday, May 21, 2026, 7:00 AM – Friday, May 22, 2026, 5:00 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY

Overview
The rapid growth of cancer therapeutics has improved outcomes and survival for many patients while introducing new and significant cardiovascular risks—underscoring the importance of cardio-oncology at the critical intersection of cancer and heart health. This symposium will deliver a comprehensive, case-based curriculum that highlights the latest advances in cancer care alongside evidence-based strategies for the prevention, early detection, and management of cardiovascular disease in patients with cancer.
This year’s program features expert-led lectures, interactive case discussions, showcasing new research and emerging evidence shaping the future of the field. Designed for clinicians, researchers, and trainees, this symposium offers participants an opportunity to engage with cutting-edge science, exchange best practices, and build meaningful connections within the growing global cardio-oncology community.
Target Audience: This program is intended for cardiologists, internists, hematologists/oncologists, advanced practice providers, nurses, and other allied healthcare professionals who care for patients with cancer or are interested in the evolving field of cardio-oncology.
Objectives

Describe contemporary anti-cancer therapies—including anthracyclines, targeted agents, immune checkpoint inhibitors, CAR-T and other cellular therapies, and hormonal therapies—highlighting their mechanisms of action and roles in cancer treatment.
Outline the cardiotoxicity profiles of these therapies and explain their impact on the cardiovascular system.
Apply principles of cardiovascular risk stratification based on patient- and treatment-specific factors to guide surveillance and management.
Determine strategies for monitoring and managing cardiotoxicity, recognizing both the supporting evidence and the current gaps in knowledge.
Explain diagnostic and therapeutic approaches to cardiac amyloidosis, including recent advances in disease-modifying treatments.
Demonstrate the principles of permissive cardiotoxicity and apply them to specific clinical scenarios.
Summarize the role and optimal use of cardiovascular imaging modalities in contemporary cardio-oncology, guided by current guidelines and best practices.
State the late cardiovascular sequelae of cancer treatment and outline best practices for managing the cardiovascular health of adult survivors of childhood and adolescent cancers.
Illustrate the unique challenges and strategies for managing acute cardiovascular disease in patients actively undergoing cancer therapy.

+ Topics:

Thursday, May 21, 2026

Setting the Stage: The Evolving Landscape of Cardio-Oncology
8:10AM – 8:25AM
Jennifer Liu, MD

Fundamentals of Antitumor Immunity and Current Applications in Solid Tumors
8:25AM – 8:40AM
James Smithy, MD

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Current Approaches and New Frontiers
8:40AM – 8:55AM
Alexander Lyon, MA, BM, BCh, PhD

Case Discussion The Spectrum of ICI Myocarditis: Clinical Lessons from Mild to Fulminant Presentations
8:55AM – 9:10AM
Carol Chen, MD
Marie-Claude Beaulieu, MD, Cardiology Fellow

Q&A Discussion
9:10AM – 9:20AM

Updates on Contemporary Lung Cancer Diagnosis and Treatment: A Primer for the Non-Oncologist
9:25AM – 9:40AM
Helena Yu, MD

Cardiovascular Considerations Associated with Lung Cancer Treatment: Screening, Diagnosis, and Management
9:40AM – 9:55AM
Anthony F Yu, MD

Q&A and Discussion
9:55AM – 10:10AM

Contemporary Management of Prostate Cancer: Hormonal Therapy, Radiation and Surgery — What Factors Influence Treatment Decisions?
10:25AM – 10:40AM
Karen Autio, MD

Screening and Managing Treatment-related Cardiotoxicity
10:40AM – 10:55AM
Krishan K Sharma, MD, MS

Q&A and Discussion
10:55AM – 11:05AM

Contemporary Breast Cancer Treatment: From Anti-HER2 Therapy to Beyond
11:05AM – 11:20AM
Chau Dang, MD

Cardiovascular Toxicities in Modern Breast Cancer Therapy: Updates on Screening and Management
11:20AM – 11:35AM
Anthony F Yu, MD

Q&A and Discussion
11:35AM – 11:45AM

How to Train in Cardio-Oncology — Cardio-Oncology Fellowship Programs
11:45AM – 12:00PM
Dipti Gupta, MD, MPH

Understanding Stem Cell/Bone Marrow Transplant — When, for Whom and Why?
1:00PM – 1:15PM
Brian Shaffer, MD

Cardiovascular Challenges During and After Bone Marrow Transplant: Mitigating Risk and Optimizing CV Health
1:15PM – 1:30PM
Daniel Addison, MD

Advances in T-Cell Therapies for Hematologic Cancers: CAR T, Bispecific Antibodies, and Beyond
1:30PM – 1:45PM
Miguel Perales, MD

T-Cell Immunotherapies and the Heart: Risks, Detection, and Management
1:45PM – 2:00PM
Eric H Yang, MD, FACC, FASE, FAHA

Q&A and Discussion
2:00PM – 2:20PM

Multiple Myeloma and AL amyloidosis: A Primer on Diagnosis and Management
2:20PM – 2:35PM
Heather J Landau, MD

Cardiac Amyloidosis: Unmasking the Great Masquerader — When to Suspect, How to Diagnose
2:35PM – 2:50PM
Richard Cheng, MD

Managing Patients with TTR Amyloidosis: Progress and Challenges
2:50PM – 3:05PM
Daniel McDonald, MD

Q&A and Discussion
3:05PM – 3:20PM

Venous Thromboembolism in Cancer Patients: Risk Assessment, Prevention and Treatment
3:35PM – 3:50PM
Jeffrey Zwicker, MD

Cancer-Associated Stroke: Etiology, Detection, and Management
4:05PM – 4:20PM
Babak Navi, MD

International Cardio-Oncology Society: Opportunities for Collaboration, Research, and Education
4:35PM – 4:50PM
Michael Fradley, MD

Friday, May 22, 2026

Laying the Foundation for Precision Cardio-Oncology: Defining Risk, Outcomes, and Surveillance
8:00AM – 9:00AM
Saro Armenian, DO, MPH

A Decade in Review: Top Research Studies and Clinical Trials in Cardio-Oncology
9:05AM – 9:20AM
Alexander Lyon, MA, BM, BCh, PhD

Precision Imaging in Cardio-Oncology: Leveraging Echo and CMR for Risk Stratification and Early Detection
9:25AM – 9:40AM
Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE

Biomarkers in Risk Prediction and Diagnosis
9:40AM – 9:55AM
Joshua D Mitchell, MD, MSCI, FACC, FICOS

MR Imaging of Cardiac Masses: Clinical Applications and Prognostic Implications
9:55AM – 10:10AM
Jonathan Weinsaft, MD

Q&A and Discussion
10:10AM – 10:25AM

Atrial Fibrillation and Cancer: Pathophysiology and Management Algorithm
10:45AM – 11:00AM
Michael Fradley, MD

Management of Cardiac Implantable Devices During Radiation, MRI, and Emerging Treatment Modalities
11:00AM – 11:15AM
Michael Fradley, MD

Q&A and Discussion
11:15AM – 11:25AM

Radiation Induced Heart Disease: A Practical Guide to Diagnosis and Management
11:25AM – 11:40AM
Joshua D Mitchell, MD, MSCI, FACC, FICOS

Radiation Therapy: Current and Future Strategies to Minimize Radiation Induced Cardiotoxicity
11:40AM – 11:55AM
Lior Braunstein, MD

Q&A and Discussion
11:55AM – 12:05PM

Late Onset Cardiotoxicity in Adult Survivors of Childhood Cancer: Incidence, Risk Factors, and Individual CV Risk Prediction
1:00PM – 1:15PM
Anju Nohria, MD, MS, Professor

Clonal Hematopoiesis: Redefining Cardiovascular Risk in Oncology and Beyond
1:15PM – 1:30PM
Saro Armenian, DO, MPH

Pharmacologic Cardioprotection in Oncology: GDMT and Beyond?
1:30PM – 1:45PM
Anita Deswal, MD, MPH, Professor of Medicine, Chair of Cardiology

Exercise as Cardioprotection in Oncology: From Evidence to Clinical Practice
1:45PM – 2:00PM
Jessica Scott, PhD

Cardio-Oncology Care and Health Equity: Challenges and Opportunities
2:00PM – 2:15PM
Michelle Johnson, MD, MPH

Q&A and Discussion
2:15PM – 2:40PM

2022 ESC Cardio-Oncology Guidelines: Where We Go From Here
2:55PM – 3:10PM
Teresa Lopez-Fernandez, MD

Advanced HF Management in Cardio-Oncology
3:10PM – 3:25PM
Jayant Raikhelkar, MD

5FU Induced Chest Pain: Diagnostic and Management Algorithm
3:25PM – 3:40PM
Stephanie Feldman, MD

Navigating Cardiac Interventions in Patients with Active Cancer: Insights from Evidence and Experience
3:40PM – 3:55PM
Dmitriy Feldman, MD

Q&A and Discussion
3:55PM – 4:15PM

CASE 1 Dexrazoxane for Cardioprotection
4:15PM – 4:25PM
Anthony F Yu, MD

CASE 2 Permissive Cardiotoxicity
4:25PM – 4:35PM
Jennifer Liu, MD

Role of Second-Line Immunosuppressants in ICI Myocarditis: When and for Whom?
4:35PM – 4:45PM
Dipti Gupta, MD, MPH